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A B S T R A C T
In order to study the possible role of nitric oxide (NO) in the human placenta, we measured the concentration of its
stable metabolite nitrite (NO2–) in the placentas of women with normal pregnancies and those from pregnancies compli-
cated by intrauterine growth restriction (IUGR) with or without fetal hypoxia. We have measured nitrites by the Griess
reaction in 15 placentas from IUGR pregnancies and 12 controls. Cerebroumbilical ratio (C:U) was recorded by color
Doppler ultrasound and values below 1 were considered to be a predictor for fetal hypoxia. NO2– levels measured in pat-
hological placentas were increased for at least 93 % as compared to control. Subjects from pregnancies complicated by
IUGR and fetal hypoxia had increased NO2– as compared to the placentas from pregnancies with IUGR and normal fetal
oxygenation. NO production in placenta is increased in pregnancies with IUGR. This effect is more pronounced in those
with compromised fetal oxygenation.
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Introduction
The sufficient blood supply with oxygen and nutritive
substances is essential for the normal growth and devel-
opment of the fetus. Deprivation of oxygen and nutrients
leads to intrauterine growth restriction (IUGR) and fetal
hypoxia. Newborns with IUGR are at increased risk to
develop a metabolic syndrome later in life, namely obe-
sity, arterial hypertension, hypercholesterolemia and car-
diovascular disease and diabetes mellitus type 21. Acute
and chronic hypoxic insults are the leading causes of pe-
rinatal brain damage, as well as the fetal and neonatal
morbidity and mortality2,3. Placental insufficiency that is
characterized by altered fetoplacental circulation is con-
sidered to be the main cause of fetal growth restriction
and hypoxia4. According to literature, placenta lacks au-
tonomic innervations and placental blood flow is regula-
ted by humoral agents (e.g. endothelin-1, prostaglandins,
tromboxane A2) and certain autocrine-paracrine mecha-
nisms5–8. Nitric oxide is thought to be the most impor-
tant vasodilatator in placenta and uterus9. Its function is
to regulate vascular tone, to attenuate the effect of vaso-
constrictors such as tromboxane A210 and endothelin-111,12
and to limit platelet adhesion and aggregation13. Nitric
oxide is generated from the metabolism of L-arginine by
the enzyme nitric syntethase (NOS)14. The constitutive
isoform of NOS has been found in the endothelial cells of
arteries and veins of umbilical cord and chorionic plate15.
Nitric oxide diffuses from generating cells to underlying
vascular smooth muscle cells and activates guanilate-
-cyclase, thus initiating chain of biochemical reactions,
which reduce Ca2+ entrance in smooth muscle cells. The
results are relaxation of those cells and consequently, va-
sodilatation16.
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Nitric oxide production is regulated by various hu-
moral agents and mechanical stimuli such as shear stre-
ss17,18. Some studies have shown that shear stress, which
can be induced by altering arterial blood flow and/or by
increased viscosity, can increase NO generation in pla-
centa18. Experimental results have indicated that angio-
genic peptide vascular endothelial growth factor (VEGF)
stimulates the proliferation and NO production in endot-
helial cells and increases their permeability19–21. VEGF
shares significant sequence homology (53%) at the amino
acid level with placental growth factor (PIGF), which in-
hibits basal release of NO from trophoblast during the
first trimester of gestation17,22. Hormones such as corti-
sol23, estrogen and progesterone24, atrial natriuretic pep-
tide (ANP)25, as well as angiotensin26 also participate in
NO production. Even the certain vascoconstrictors such
as endothelin, may mediate a paradoxical vasodilatation.
Their interaction with some endothelial receptors results
with the release of the relaxation factor such as NO and
prostacyclin PGI227–29. All those humoral factors could be
very important during pregnancy as well as during nor-
mal menstrual cycle17.
Some results indicate that in pathological conditions,
such as preeclampsia and intrauterine growth restric-
tion, the increased vascular resistance in placental bed
might be the result of the impaired production of NO30.
On the other hand, the higher production of NOmight be
compensatory response in preeclampsia and IUGR,
which leads to vasodilatation and insures the supply of
the fetus with oxygen and nutritive substances31. In sup-
port to these findings, other researchers have reported
higher levels of NO metabolites in those pathological
conditions32,33. Obviously, the reports of the effect of NO
in IUGR and preeclampsia are still quite controversial
and its real contribution to these conditions remains to
be elucidated.
Fetus is able to activate a wide specter of cardiovascu-
lar, biophysical, biochemical and endocrinological adapti-
ve mechanisms in reaction to hypoxia. Fetal cardiovascu-
lar responses to hypoxia are considered the most impor-
tant adaptive mechanisms responsible for maintaining
fetal homeostasis. They are coordinated to redistribute
blood flow to organs important for the survival of the fe-
tus, such as the brain, heart and adrenals34. This redis-
tribution of fetal blood flow can easily be detected by
Doppler ultrasound. The modifications of placental he-
modynamics, responsible for IUGR and hypoxia, can be
quantified using the umbilical resistance index (URI),
measured on the umbilical arterial velocity waveforms.
The cerebrovascular adaptation (vasodilatation) can be
assessed using the cerebral resistance index (CRI), mea-
sured on the middle cerebral artery velocity waveforms35.
Many studies have shown that the best indicator of the
fetal blood flow redistribution between the placenta and
the brain is cerebro-umibilical ratio (C:U ratio=CRI:U-
RI)35,36. Namely, in uncomplicated pregnancies, vascular
resistance in cerebral arteries remains higher than in
umbilical arteries; therefore C:U ratio is always higher
than 136, 37. If any blood flow redistribution in favor of the
fetal brain occurs, the C:U ratio becomes less than 1. Mo-
reover, it is one of the most sensitive parameters for
detection and quantification of fetal hypoxia38. It has
been shown that the decrease in C:U ratio (below 1)
strongly correlates with the reduction in pO2 in fetal
blood during acute39 as well as chronic hypoxia40.
The aim of our study was to assess the umbilical he-
modynamic changes and the blood flow redistribution to-
wards the fetal brain in growth restricted fetuses and to
determine the concentrations of NO metabolites in pla-
centas from pregnancies complicated by growth restric-
tion with or without fetal hypoxia.
Materials and Methods
Patients
The study included pregnant women with normal,
term delivery (n=12) and women with pregnancies com-
plicated by IUGR (n=15) from 33 to 42 weeks of gesta-
tion. The term intrauterine growth restriction was defi-
ned as an estimated fetal weight (calculated on the basis
of ultrasound fetal biometry) below the 10th percentile
for the local reference values for gestational age and gen-
der, and at the same time growth rate slower than nor-
mal along a standardized growth curve41. Maternal and
fetal clinical characteristics, which were taken into consi-
deration, where age, parity, nicotine abuse and fetal sex.
The pregnancy outcome was assessed according to the
mode of delivery, gestational age, birth weight, birth len-
gth and placental weight. Patients with hypertension
(blood pressure in three consecutive measurements over
130/85 mmHg), preeclampsia, diabetes mellitus, cho-
rioamnionitis or any type of maternal infections were ex-
cluded from our study. Fetuses with congenital anoma-
lies and suspected intrauterine infections were also
excluded from the study. The study was conducted in the
Clinical Hospital Sestre Milosrdnice Zagreb, Croatia and
was approved by the local ethical committee.
Placental tissue collection and preparation of
villous homogenate
Placental tissue samples were taken immediately
upon delivery. Three tissue blocks (20  20 mm), one in
close proximity to the umbilical cord insertion and two
from randomly chosen spots at the periphery, were cut
from each placenta and used for determination of NO
metabolites. Three different samples were taken from
each placenta assuming that blood flow perfusion varies
in different parts of placenta. Placental samples were
washed in PBS and 1.5 grams of wet tissue weight were
taken from each sample. The samples were manually ho-
mogenized and then centrifuged for 10 minutes at 3000
RPM. The supernatants were deproteinized with ZnSO4
and after centrifugation prepared for determination of
NO metabolites.
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Determination of NO metabolites
NO2– concentration was determined using the classi-
cal Griess reaction42. Briefly, 0.1 ml of placental homoge-
nates was pipetted into the wells of flat-bottomed 96-well
microtitration plates, followed by addition of 0.1 ml of
Griess solution. The plate was shaken for 10 min at room
temperature, after which purple color developed in posi-
tive plates. The plates were read in a microplate reader
at optical density of 550 nm.
Chemicals
The following chemicals were used for sample prepa-
ration and determination of NO metabolites: PBS, zinc-
-sulfate (ZnSO4) and Griess solution. Griess reagent was
formed of 2% sulfanilamide in N-1-naphthylethylenedia-
mine and 0.2% sulfanilamide in distillated water. Griess
solutions were purchased by Sigma, St Louise, USA and
zinc-sulfate was purchased by Kemika, Zagreb, Croatia.
Doppler indices
Intrauterine growth restriction (n=15), detected by
ultrasound biometry, was an indication for color Doppler
assessment. Examinations were carried out using the
Aloka 2000 (Aloka, Japan) ultrasonic device with tran-
sabdominal probe, with a frequency of 3.5 and 5 MHz
(maximum emission energy of the device is below the li-
mits approved for use in fetal medicine, SPTA <80 mW/
cm2 for B mode). Blood flow velocity waveforms were re-
corded from the umbilical artery and middle cerebral ar-
tery by serial measurements with an interval of at least
one week in the period from 33 weeks of gestation until
delivery. Changes in the placental hemodynamics were
quantified by using the umbilical artery resistance index
(URI) and cerebrovascular adaptation was quantified by
using the middle cerebral artery resistance index (CRI).
The resistance indices were calculated on the basis of
Doppler records of at least 6 sequential heart cycles. The
blood flow redistribution between the placenta and the
brain was detected and quantified by the C:U ratio ex-
pressed as CRI:URI.
Statistics
The Mann-Whitney test was used to compare the con-
centrations of NO metabolites between control and
IUGR group. The same test was used to assess the differ-
ences in NO production between two subgroups of IUGR:
one with C/U<1 and second with C/U>1. Quality variab-
les such as: parity, mode of delivery, fetal sex and nicotine
abuse between pregnant women with uncomplicated, in
term delivery and women with fetal growth restriction
were compared by using Fisher’s Exact test. Quantitati-
ve variables such as: maternal age, gestational age, birth
weight, birth length and placental weight between wo-
men with complicated, in term delivery and women with
IUGR were compared by using Mann-Whitney test. To
assess if there were differences between concentrations
of NO metabolites from three samples (one insertion and
two from periphery) Friedman test was used. In all tests,
differences were considered to be significant if P<0.05.
Results
Patient characteristics of our interest were divided
into qualitative and quantitative variables. Qualitative
clinical characteristics: parity (primigravid or multigra-
vid), mode of delivery (vaginal or Cesarean section), fetal
sex (male of female) and nicotine abuse (smokers or non-
-smokers) are shown in Table 1. Quantitative character-
istics: maternal age, gestational age, birth weight, birth
length and placental weight are shown in Table 2. There
were no significant differences in parity, fetal sex and ni-
cotine abuse between uncomplicated pregnancies and
pregnancies with lUGR. Those findings allowed us to
make comparisons between these two groups. Regarding
the nicotine abuse, the number of cigarettes smoked per
day was not recorded. Also, the majority of our patients
(Table 1) were non-smokers. Potential influence of nico-
tine abuse on NO production has to be investigated on a
larger population.
The pregnancy outcome was worse in the IUGR group.
We found significant differences in mode of delivery (vag-
inal or Caesarean section) between IUGR and control
group. Namely, the number of Caesarean sections for fe-
tal distress was significantly higher in IUGR group (Ta-
ble 1). Furthermore, the gestational age was shorter and
the newborn and placental weight was decreased in the
pregnancies complicated by IUGR. Birth length was sig-
nificantly shorter in IUGR than in the control group
(P<0.05, Table 2). The mean maternal age was signifi-
cantly higher in the IUGR group (P<0.05, Table 2).
The mean total concentration of nitrites measured in
the placental supernatants was about 15 times higher in
the IUGR group than in the control group (Figure 1).
The results showed that there were no significant differ-
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TABLE 1
QUALITATIVE CLINICAL PARAMETERS OF PATIENTS WITH
NORMAL PREGNANCIES AND PATIENTS WITH INTRAUTERINE
GROWTH RESTRICTION (IUGR)
Parameters Control (n=12) IUGR (n=15)
Parity (No)
Primigravid
Multigravid
8
4
7
8
Fetal sex (No)
Male
Female
6
6
6
9
Mode of delivery (No)
Vaginal
Cesarean section
11
1
4
11*
Nicotin abuse (No)
Smokers
Non-smokers
2
10
4
11
Statistically significant differences are indicated by * (P0.05),
No number
ences in concentration of NOmetabolites between center
and periphery of placentas (Figure 1).
All patients with pregnancies complicated with IUGR
had increased values of URI (Figure 2), which lead us to
conclusion that their placental perfusion was compromi-
sed and pathological. The IUGR group was subdivided
according to the value of C:U ratio into two subgroups:
one with the C:U<1 (n=7) and the other with C:U  1
(n=8). Cerebral-umbilical ratio less then 1 indicated the
fetal blood flow redistribution towards the brain as a res-
ponse to fetal hypoxia.
Total nitrites levels were examined separately in each
subgroup (Table 3). It was found clearly that NO produc-
tion was significantly higher in placentas of patients
with C:U<1 as compared to the patients with C:U  1
(P<0.05).
Discussion
Intrauterine growth restriction is a common clinical
problem which can lead to long-term metabolic conse-
quences, such as an increased propensity for some of the
most common diseases of adult life43. Among the many
potential underlying processes, placental insufficiency is
believed to be the most important cause of intrauterine
growth restriction44,45. We showed that placentas from
pregnancies complicated by IUGR had decreased weight
as compared to control (Table 2). Many authors have re-
ported that placentas from pregnancies complicated by
IUGR never reach their total growth potential. They are
smaller, circulatory compromised and therefore cannot
fulfill their nutritional function44,46. Furthermore, in
pregnancies complicated by lUGR placenta is often rec-
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TABLE 2
QUANTITATIVE CLINICAL PARAMETERS OF PATIENTS WITH NORMAL PREGNANCIES AND PATIENTS WITH INTRAUTERINE
GROWTH RESTRICTION (IUGR)
Parameters Mean Stanard Error Median Range Minimum Maximum
Maternal age (years)
Control
IUGR
25.7
29.7*
1.4
1
25
29
19
15
19
23
38,8
38
Gestational age (weeks)
Control
IUGR
39.9
36.7*
0.3
0.5
40.3
36.5
3
6
38.5
33.5
41.5
39.5
Birth weight (g)
Control
IUGR
3416.7
2191.3*
92.1
103.8
3340
2220
920
1300
2980
1400
3900
2700
Birth length (cm)
Control
IUGR
50.3
44.8*
0.6
0.6
50
46
8
8
47
40
55
48
Placental weight (g)
Control
IUGR
547.5
407.3*
16.5
21.8
510
440
150
290
500
210
650
500
Statistically significant differences are indicated by * (P<0.05)
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Fig. 1. Mean total concentrations of nitric oxide (NO) metabolites
in three samples of placenta (one from umbilical cord insertion
and two from periphery), bars indicate standard error of the mean.
Statistically significant differences are indicated by * (P<0.05).
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Fig. 2. Changes of umbilical artery resistance index (URI) mea-
sured by Doppler assessment through gestation in patients with
intrauterine growth restriction (IUGR) as compared to control.
ognized as being in a state of villous immaturity for ges-
tational age and having terminal villi deficiency47.
The relationship between maternal and fetal circula-
tion in the placenta is crucial for efficient exchanges of
oxygen and nutrients48. Since placenta lacks nervous au-
tonomic innervations, humoral factors are considered to
be the most important blood flow regulators. Different
humoral factors are considered to have an affect on NO
production in the human organism17–22. Since NO has
short half-life, we have measured the concentration of its
stable metabolites nitrite by the Griess reaction. The
Griess reaction was previously shown to be sensitive for
determination of these molecules42. Our results, rather
higher concentrations of NO2– in samples of placentas
from pregnancies with IUGR and fetal hypoxia (Figure
2), implicate the activation of compensatory blood flow
regulation mechanisms on the placental level. It means
that the increase in NO production could be one of the
compensatory reactions to reduced placental blood flow
and hypoxia. Some investigators have shown reduced
output of nitric oxide in pregnancies with IUGR49,50,
while in several other studies concentration of NO meta-
bolites was increased as compared to normal51,52. Never-
theless, we have to emphasize that in all of these studies,
concentration of NOmetabolites was measured fromma-
ternal serum and umbilical vein. However, none of the
investigators used placental tissue for measurements of
NO concentration in IUGR pregnancies. Shaamash et
al.31 used placental tissue, but in pregnancies complica-
ted by pre-eclampsia and eclampsia. They also reported
higher concentrations of NOmetabolites in patients with
preeclampsia and eclampsia as compared to normal preg-
nancies31.
Normal placental function depends on maintenance
of uteroplacental perfusion48. Our previous studies have
revealed the existence of physiological cardiovascular
compensatory mechanisms on the placental level that
protect the fetal vital organs, particularly the brain, dur-
ing hypoxia4,53. That results in the blood flow redistribu-
tion in favor of the fetal brain which can be detected and
quantified using the C:U ratio. That ratio takes into ac-
count umbilical vascular resistance and the cerebral res-
ponse to hypoxia. Values of C:U ratio less than 1 are con-
sidered as an indicator of compromised fetal oxygenation.
We detected increase of umbilical vascular resistance in
our patients with IUGR (Figure 2) which is thought to be
the result of the disturbed placental perfusion. Such in-
crease is often detected in color Doppler studies of preg-
nancies complicated by IUGR37,39. Arabin and co-workers
found that only 7% of placentas with absent end-diastolic
umbilical flow were normal54. They noted evidence of
chronic placental insufficiency, manifested by small pla-
cental villi, fibrosis and microfibrinous deposits in 74%
placentas. The remaining 19% showed a reduced perfu-
sion capacity. This increase of impedance to flow in the
umbilical artery is associated with hypoxia and a poor pe-
rinatal outcome54.
We found the difference in NO production between
the two subgroups of IUGR divided according to the va-
lue of C:U ratio (Table 3). Placental NO was released in
significantly higher amounts in IUGR pregnancies with
disturbed fetal oxygenation (C:U ratio less then 1) as
compared to the IUGR control pregnancies (C:U ratio
more then 1). Our results suggested that placental NO
production depends on the severity of IUGR, as indicated
by fetal oxygenation, at least when it is not accompanied
with other pathological conditions, such as preeclampsia.
To our knowledge, this study is first to assess the NO
production in pregnancies with lUGR according to the
C:U ratio, as the indicator of fetal oxygenation. Most of
the authors assess the placental function according to
the umbilical resistance indices55,56. However, only the
strong disturbances of umbilical resistance, such as ab-
sent end diastolic blood flow, have a good sensitivity in
the assessment of fetal condition55. The fetal oxygenation
can be either normal or decreased in case of the some-
what compromised placental function and slightly in-
creased umbilical resistance. The most precise evalua-
tion of fetal pO2 could be obtained using the C:U ratio. It
takes into account the fetal cerebrovascular response to
hypoxia, as well as the placental impairment53,57. Moreo-
ver, C:U ratio is used for calculation of hypoxia index (the
sum of daily reductions in C:U ratio over the period of ob-
servation) which is suggested to be predictor of a poor
neurological outcome in pregnancies complicated by
growth restriction and hypoxia58.
To summarize, our results have shown a significant
increase in total placental nitrite production in pregnan-
cies complicated by IUGR, especially when is accompa-
nied with fetal hypoxia. Such increase possibly repre-
sents a physiologic adaptive response to overcome the
increase placental vascular resistance. Our conclusion is
that NO plays an important role in the activation of com-
pensatory blood flow regulation mechanisms on the pla-
cental level during IUGR and fetal hypoxia.
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TABLE 3
TOTAL NITRITE LEVELS IN PLACENTAS OF PATIENTS WITH
INTRAUTERINE GROWTH RESTRICTION (IUGR)
Cerebro- umbilical ratio (C/U) C/U1
(N=7)
C/U 1
(N=8)
Placental total nitrites (mMol/L) 69.75 ± 18.85* 39.15 ± 8.83
Patients with IUGR pregnancies are subdivided into two groups
according to the cerebro-umbilical ratio (C/U): C/U<1 and
C/U1. Date are given as mean  standard error of the mean.
Statistically significant difference is indicated by* (P<0.05).
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SINTEZA DU[IKOVOG MONOKSIDA U POSTELJICI JE POVE]ANA KOD INTRAUTERINOG
ZASTOJA U RASTU I FETALNE HIPOKSIJE
S A @ E T A K
Kako bismo istra`ili mogu}u ulogu du{ikovog monoksida (NO) u ljudskoj posteljici mjerili smo koncentracije njego-
vih stabilnih metabolita nitrita (NO2) u posteljicama `ena s normalnim trudno}ama, kao i kod onih s fetalnim zastojem
u rastu sa ili bez hipoksije. Koncentraciju nitrita odre|ivali smo pomo}u Griessove reakcije kod 12 posteljica iz trudno}a
kompliciranih zastojem u rastu, te kod 12 kontrola. Cerebroumbilikalni omjer (C/U) odre|ivan je pomo}u ultrazvu}nog
obojenog Dopplera, a njegove vrijednosti manje od 1 smatrane su dobrim pokazateljima fetalne hipoksije. Vrijednosti
NO2– mjerene u posteljicama iz patolo{kih trudno}a su najmanje za 93 % uve}ane u usporedbi s kontrolom. [tovi{e, pos-
teljice iz trudno}a s fetalnim zastojem u rastu i fetalnom hipoksijom imaju znatno ve}e koncentracije NO2– u usporedbi
s posteljicama s fetalnim zastojem u rastu, ali s normalnom fetalnom oksigenacijom. Stvaranje du{ikovog monoksida je
pove}ano u posteljicama trudno}a s fetalnim zastojem u rast. Taj je efekt jo{ izra`eniji ako je, uz zastoj u rastu, kompro-
mitirana i fetalna oksigenacija.
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